BioSpace News Archive

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and Navigo Proteins GmbH (“Navigo”), a premier protein engineering company specializing in novel affinity ligand development, today announced that they have completed the development and initiated the commercial launch of NGL COVID-19 Spike Protein Affinity Resin

Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that it has sold its neurology portfolio to Azurity Pharmaceuticals.

IntelGenx Corp. (TSX-V:IGX) (OTCQB:IGXT) (“IntelGenx”) today announced that it has filed a new provisional patent application at the United States Patent and Trademark Office entitled “High Loading Oral Film Formulation.”

Biotricity, Inc. (OTCQB:BTCY), a medical diagnostic and consumer healthcare technology company, today announced that it will discuss the highlights of its financial results for the third quarter of fiscal 2021, ended December 31, 2020, on Thursday, February 11, 2021, after the close of the market.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021

Palleon Pharmaceuticals, a company pioneering the field of glycan-mediated immune regulation to treat cancer and inflammatory diseases, today announced the appointment of Nikola Trbovic, Ph.D., Executive Director and Partner at Pfizer Ventures, as a member of its Board of Directors.

Skyworks Solutions, Inc. (Nasdaq: SWKS), an innovator of high-performance analog semiconductors connecting people, places and things, today announced that executives will participate in the Goldman Sachs 2021 Technology and Internet Conference at 2:40 p.m. EST on Feb. 11, 2021.

NTT Research, Inc., a division of NTT (TYO:9432), today announced that its Medical & Health Informatics (MEI) Lab has entered a joint research agreement with Japan’s National Cerebral and Cardiovascular Center (NCVC) to develop cardiovascular disease-related computational models, implement them on a bio digital twin platform and develop applications for use by physicians and patients.

Xcelerate, Inc. (OTC: UDHI) is pleased to announce that Dr. Dilan Ellegala has accepted an invitation to join its Advisory Board, effective immediately.

Incoming leader to oversee fundraising to share trustworthy information about cancer for patients and caregivers as well as supporting promising early-career cancer researchers.